On this page
What is the difference between patent information, patent certification and FDA exclusivity?
Patent information identifies qualifying patents for an NDA product. Patent certification addresses relevant patents for a relying ANDA or 505(b)(2) application. An exclusivity claim has a separate regulatory and evidence basis. Establish the applicant’s role, pathway, product and proposed reliance before choosing the document; one program can involve more than one task.
Before you begin
Primarily NDA, 505(b)(2) and ANDA administrative tasks. BLA patent and exclusivity frameworks are not interchangeable with Orange Book rules.
What you will prepare: A routed worklist based on application pathway, product and proposed reliance.
Ask whose application and whose patent are involved
Patent information in 1.3.5.1 concerns the NDA applicant or holder’s submission of qualifying patent information under §314.53. Patent certification in 1.3.5.2 concerns the relevant listed-drug patents for an ANDA or 505(b)(2) application under §§314.94(a)(12) or 314.50(i). Exclusivity in 1.3.5.3 requires a separate legal and evidentiary basis; a patent is not an exclusivity award.
These tasks can coexist. A 505(b)(2) applicant may have obligations involving its own qualifying patents and certifications to the listed drug on which it relies. Do not infer the correct document from the single word “patent.”
Collect a pathway-specific evidence pack
Record application pathway, pending/approved stage, product strengths, proposed uses, relied-on listed drug, patent records, labeling and the precise exclusivity basis under consideration. Have regulatory and patent counsel resolve the classification and legal judgments. The author’s role is to make the facts and proposed filing traceable.
Fictional exercise: a team wants to submit Form 3542 to explain why its generic product does not infringe the reference product’s patent. That is the wrong task: the ANDA patent-certification process requires a pathway-specific determination and, where applicable, notice work. Change the scenario to the NDA holder reporting its own newly issued qualifying patent: the information-submission workflow becomes relevant. With no pathway provided, the result is undetermined, not an assumed Paragraph IV certification.
Route the request before asking for a patent template
Use this decision sheet when an intake request only says “patent documents.” Its purpose is to identify the work and evidence owner, not to determine a patent’s legal scope.
| Task | Question that selects it | Principal output |
|---|---|---|
| NDA patent information | Are we submitting qualifying patent information for the product in our NDA? | Appropriate 3542a/3542 information and declaration |
| Reliance-related certification | Which listed drug and patents are relevant to our ANDA or 505(b)(2) application? | Patent-by-patent certification or applicable statement, plus notice assessment |
| NDA exclusivity claim | Which specific regulatory category do the application’s facts support? | Claim, required supporting material and evidence locations |
Add the application number or pending application identity, approval stage, product/use, relied-on drug where relevant, responsible counsel and intended submission event. Resolve these fields before assigning the author a standard letter. The patent team may supply one portfolio list, but the regulatory tasks do not all use that list in the same way.
Mixed-work exercise: a 505(b)(2) team has a formulation patent, relies on a listed drug and believes a new investigation supports exclusivity. Create three work items. The formulation patent needs its own eligibility and information-submission assessment; reliance needs the appropriate certifications or statements; exclusivity needs an independent evidence analysis. Completing one item does not close the others.
Use the patent-information guide, certification guide and exclusivity guide after routing. If the application is a BLA, record that the NDA/ANDA framework here does not establish the appropriate biologic procedure. Preserve the factual intake without forcing it into an Orange Book template.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Can a 505(b)(2) application need both patent information and patent certifications?
Yes. Its own qualifying patent-information task and its certifications or statements relating to relied-on listed drugs are distinct. Identify the relevant product, patent and applicant role for each item. A completed form for one task is not evidence that the other has been addressed.
Does owning a patent establish entitlement to FDA exclusivity?
No. The NDA exclusivity provisions apply their own eligibility tests and supporting-information requirements. Patent ownership may be relevant to a separate patent-information task, but it does not establish active-moiety history, qualifying clinical investigations or the other elements of an exclusivity claim.
Is Form 3542 used to explain why an ANDA does not infringe a listed patent?
No. Form 3542 concerns patent information for an approved NDA product or use. An ANDA’s position on a relevant listed patent belongs in the applicable certification or statement process, with separate notice work where required. Establish that task before preparing the document.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 314: drug marketing applications ↗Current part reopened September 22, 2026; §§314.50, 314.53, 314.65, 314.72, 314.94, 314.99, 314.108 and 314.150–162 inspected. Not a general BLA rule.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.3.5. A heading identifies placement, not mandatory applicability.